// App-Quantinova.ai

CTIM-20 : FINAL RESULTS OF CONTROLLED IL-12 MONOTHERAPY AND IN COMBINATION WITH PD-1 INHIBITOR IN ADULT SUBJECTS WITH RECURRENT GLIOBLASTOMA

Researchers

Presenter

  • Rimas Lukas

Principal Investigators

  • Nancy Ann Oberheim-Bush

  • Robert Cavaliere

  • Joseph Landolfi

  • John S Yu

  • Clark Chen

  • Christine Cordova

  • Christina Amidei

  • Jill Y Buck

  • Nira Hadar

  • Nate Demars

  • John Miao

  • John Loewy

  • Taylor Estupinan

  • Kamal Chadha

  • Laurence J N Cooper

  • E Antonio Chiocca

Medical Centers

  • JFK Medical Center, HMH Jersey Shore University Medical Center, Neptune, USA

  • University of Minnesota, Minneapolis, USA

  • Baptist MD Anderson Cancer Center, Jacksonville, FL, USA

  • Cedars Sinai, L.A, USA

  • Northwestern University, Chicago, USA

  • NYU Grossman School of Medicine, New York, USA

  • Harvey Cushing Neuro-oncology Laboratories, Department of Neurosurgery, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA, Boston, MA, USA

  • Division of Neuro-Oncology, University of California, San Francisco, CA, USA

  • ziopharm, Boston, USA

  • Northwestern Medicine Lou and Jean Malnati Brain Tumor Institute, Chicago, IL, USA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Oncology (ONC)

Disease

  • Glioblastoma

  • Acro–dermato–ungual–lacrimal–tooth (ADULT) syndrome

Biomarkers

  • N/A

Drug/Treatment

  • Ad-RTS-hIL-12

  • Nivolumab

  • IL-12

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

  • Multicenteric

  • Controlled

Phase

  • I

Study Id's

  • NCT03679754

  • NCT03636477

  • NCT04006119

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved